Name
Brand
Name
Classification
Salicylate
Anticoagulants,
Antiplatelets &
Fibrinolytics
(Thrombolytics)
Aspirin
TIAs in
men:1,300
mg/day in
divided doses
(650 mg bid or
325 mg qid).
Indication
Contraindicati
on
Mechanism Of
Action
Adverse Reaction
Nursing Considerati
ons
For pain
onintegumenta
rystructures,m
yalgia,neuralgi
a,headache,dy
smenorrhea,go
ut.
Hypersensitivit
y to salicylates,
severe
anemia, history
of blood
coagulation
defects,
vitamin K
deficiency, 1
week before
and after
surgery, pregn
ancy in the last
trimester.
Prevent blood
coagulation due to
hypertension (narrow
blood vessels may
cause blood to
aggregate)
GI: dyspepsia,
heartburn, anorexia,
nausea, epigastric
discomfort, potentiat
ion of peptic ulcer
Arthritis, SLE,
acute
rheumatic
fever
Exhibits
antipyretic, antiinflammatory and
analgesic effects.
The antipyretic
effect is due to an
action on the
hypothalamus,
resulting in heat
loss by
vasodilation of
peripheral blood
vessels. Antiinflammatory
effects are
mediated by a
decrease
in prostaglandin
synthesis. It also
decreases platelet
aggregation
Allergic:
Bronchospasm,
asthma-like
symptoms,
anaphylaxis, skin
rashes, urticaria
Hematologic:
prolongation of
bleeding time,
thrombocytopenia,
leucopenia,
Other: Thirst, fever,
dimness of vision
Generic
Name
Brand
Name
Warfarin
Sodium
Coumadin
Classification
Anticoagulant
Indication
Contraindicati
on
Mechanism Of
Action
Adverse Reaction
Nursing
Considerations
Prevention of
recurrent TIAs
hypersensitivit
y; hemorrhagic
tendencies or
blood
dyscrasia;
recent surgery;
peptic ulcer;
severe
hypertension;
bacterial
endocarditis;
cerebrovascula
r disorders;
psychosis;
senility;
aneurysms;
pericarditis;
pericardial
effusion;
eclampsia;
pre-eclampsia;
threatened
abortion;
alcoholism;
severe renal
and hepatic
impairment;
pregnancy.
hypersensitivity,
rash, alopecia,
diarrhea, drop in
hematocrit, purple
toes syndrome, skin
necrosis, jaundice,
nausea, vomiting,
hepatic dysfunction,
pancreatitis,
increased LFT.
Warfarin inhibits
synthesis of vit Kdependent
coagulation factors
VII, IX, X and II
and anticoagulant
protein C and its
cofactor protein S.
No effects on
established
thrombus but
further extension
of the clot can be
prevented.
Secondary embolic
phenomena are
avoided.
Monitor PT ratio or
INR regularly to adjust
dosage.
Administer IV form to
patients stabilized on
Coumadin who are not
able to take oral drug.
Dosages are the
same. Return to oral
form as soon as
feasible.
Do not change brand
names once
stabilized;
bioavailability may be
a problem.
Keep ready vitamin K
incase of overdose.
Generic
Name
Brand
Name
Classification
Indication
Contraindic
ation
Mechanism Of
Action
Adverse Reaction
Nursing Consider
ations
Generic
Name
Brand
Name
Classification
Indication
Contraindic
ation
Mechanism Of
Action
Adverse Reaction
Nursing Consider
ations
Generic
Name
Brand
Name
Classification
Indication
Contraindic
ation
Mechanism Of
Action
Adverse Reaction
Nursing Consider
ations